IL-17 ligand-targeting inhibitors in psoriatic arthritis: a focused systematic review and network meta-analysis of efficacy, safety, and certainty of evidence.

What was studied

This review compared drugs that block IL-17 in adults with active psoriatic arthritis. The authors searched several databases for randomized trials. They used a network analysis to compare the drugs. They also rated how sure the evidence was.

What they found

All active drugs beat placebo for joint symptoms at weeks 12-16. One ixekizumab schedule ranked top. The ranges of results overlapped, though. Skin and daily function also improved. Newer drugs, sonelokimab and izokibep, looked good. Their evidence was very low in certainty. Serious side effects were not clearly higher than with placebo. Bimekizumab showed a modest rise in infections. It also showed more Candida signals.

What it means for patients

The authors say IL-17 drugs work well in the short term for active psoriatic arthritis. They say the ranks hint at some gaps within the class. They say Candida risk and patient factors should shape the choice.

Why it is not certain yet

The drug comparisons were indirect. Ranges of results overlapped, so no drug can be called clearly better. Evidence for the newer drugs was very low in certainty. Week 52 results were only described, not tested.

Source

IL-17 ligand-targeting inhibitors in psoriatic arthritis: a focused systematic review and network meta-analysis of efficacy, safety, and certainty of evidence.

We restate facts from the source record in our own words. The original wording belongs to its publisher.